Introduction {#Sec1}
============

There is evidence to suggest that early initiation of maintenance bronchodilator therapy in patients with chronic obstructive pulmonary disease (COPD) may provide benefits in lung function and health status \[[@CR1]--[@CR3]\]. A recent study also reported that dual-bronchodilator maintenance therapy with a long-acting muscarinic antagonist (LAMA) plus a long-acting β~2~-agonist (LABA) may provide improvements in lung function in treatment-naïve patients and patients with less severe COPD, as well as those already receiving maintenance therapy \[[@CR4]\].

Since many patients with COPD with moderate lung function impairment remain symptomatic with mono-bronchodilator therapy \[[@CR5]\], a rationale for the use of dual bronchodilators in these patients is emerging. The effects of early initiation of maintenance therapy with long-acting bronchodilators are not yet fully characterized, and fundamental questions remain regarding the most appropriate timing of maintenance bronchodilator therapy initiation for COPD and which patients would benefit most from dual-bronchodilator treatment versus monotherapy. To assess these points it is important to consider not just improvements but also the risk of deterioration in both lung function and health status in COPD with dual-bronchodilator versus standard LAMA monotherapy when used as either first- or second-line therapy.

Short-term clinically important deterioration (CID) is a new composite endpoint in COPD, which encompasses the occurrence of clinically significant, recognized deteriorations (termed minimal clinically important differences) in lung function, quality of life (QoL), and moderate-to-severe exacerbations that can be used as a measure of disease worsening \[[@CR6]--[@CR9]\]. This composite endpoint is consistent with current Global initiative for chronic Obstructive Lung Disease (GOLD) guidelines \[[@CR10]\], which recommend that lung function, health status, and COPD exacerbation risk are considered when assessing disease progression and severity. There are currently limited objective means to assess symptomatic patients at an early stage in the course of COPD; therefore, assessment of CID may provide useful information on how to maintain patient stability and prevent deterioration.

The objective of this pooled analysis was to compare the efficacy of the LAMA/LABA combination, umeclidinium/vilanterol (UMEC/VI), and the widely used LAMA, tiotropium (TIO), in a subgroup of maintenance-naïve (MN) patients relative to a larger intent-to-treat (ITT) population, based on lung function, health-related QoL (HRQoL), rescue medication use, and prevention of CID in patients with COPD and moderate-to-severe breathlessness.

Methods {#Sec2}
=======

Study Design, Treatments, and Patients {#Sec3}
--------------------------------------

This was a post hoc analysis (GSK analysis: 202066) of data from three multicenter, randomized, 24-week, parallel-group, blinded trials selected because they compared UMEC/VI and TIO: ZEP117115 (NCT01777334) \[[@CR11]\], DB2113374 (NCT01316913) \[[@CR12]\], and DB2113360 (NCT01316900) \[[@CR12]\].

Patients were randomized to receive once-daily inhaled UMEC/VI 62.5/25 mcg (delivering 55 mcg and 22 mcg, respectively) via the ELLIPTA™ dry powder inhaler or TIO 18 mcg via the HandiHaler^®^. Studies DB2113360 and DB2113374 also included treatment arms for once-daily UMEC/VI 125/25 mcg (delivering 113 mcg and 22 mcg) and either VI 25 mcg (DB2113360) or UMEC 125 mcg (DB2113374). Data were included in the analysis, but results are not presented in this manuscript \[[@CR11], [@CR12]\].

Patients were aged ≥40 years, had a diagnosis of symptomatic COPD \[[@CR13]\], a modified Medical Research Council Dyspnea Scale score ≥2 (i.e., all patients had moderate-to-severe breathlessness), had a post-bronchodilator forced expiratory volume in 1 s (FEV~1~) of ≤70% predicted, and an FEV~1~/forced vital capacity ratio \<0.70. Patients were excluded if they had a current diagnosis of asthma or other known respiratory condition.

All procedures followed in the studies were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the studies.

Outcomes and Assessments {#Sec4}
------------------------

The primary endpoint in all studies was change from baseline in trough FEV~1~ on day 169, defined as the mean of the FEV~1~ values obtained 23 and 24 h after dosing on day 168. St George's Respiratory Questionnaire (SGRQ) total score was assessed in each study. SGRQ responders were defined as patients who experienced a decrease from baseline of ≥4 units \[[@CR6]\]. Daily use of rescue medication was also assessed. As a minimal clinically important difference for rescue medication use is not yet defined, we pre-specified a treatment benefit of 1 rescue-free month per year or 2 rescue-free weeks out of 24 (corresponding to a change from baseline ≥8.3% in the percentage of rescue-free days over weeks 1--24) as clinically important and used this value as the definition of rescue medication responders.

This analysis was performed on a subgroup of MN patients (defined as receiving no maintenance therapy for ≥30 days before screening) and the ITT population and assessed the time to, and risk of, a short-term CID. CID was defined as: a decrease from baseline of ≥100 ml in trough FEV~1~ \[[@CR9]\], and/or an increase from baseline of ≥4 units in SGRQ total score \[[@CR6]\], and/or an on-treatment moderate-to-severe COPD exacerbation (defined as a worsening of COPD symptoms requiring use of any additional treatment other than study drug or rescue albuterol use and an emergency department visit or hospitalization). Deteriorations in trough FEV~1~ were assessed based on data from seven trial visits post-randomization (days 2, 28, 56, 84, 112, 168, and 169) and SGRQ from three study visits (days 28, 84, and 168).

Sustained CIDs were also assessed and defined as: a moderate-to-severe COPD exacerbation leading to study withdrawal, or an FEV~1~ decrease ≥100 ml or an SGRQ total score increase ≥4 units from baseline on two consecutive visits, or for ≥50% of all available subsequent visits. As the protocols from the studies mandated that patients be withdrawn from the study following a moderate-to-severe COPD exacerbation, the first incidence of a moderate-to-severe COPD exacerbation was also considered a component of sustained CID. In each study, adverse events (AEs) were monitored.

Statistical Analysis {#Sec5}
--------------------

Statistical comparisons were presented for UMEC/VI 62.5/25 mcg versus TIO. Trough FEV~1~ and SGRQ comparisons were analyzed using a repeated measures model including covariates of study, treatment, baseline score, smoking status, geographical region, day, day by baseline, and day by treatment. Comparisons of rescue-free days were analyzed using logistic regression with covariates of study, treatment, baseline percentage, smoking status, and geographical region. Comparisons of the time to a first or sustained short-term CID, and each individual component within these endpoints, were analyzed using a Cox proportional hazards model including covariates of study, treatment, smoking status at screening, and geographical region.

Compliance with Ethics Guidelines {#Sec6}
---------------------------------

All procedures followed in the studies were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964, as revised in 2013. Informed consent was obtained from all patients for being included in the studies.

Results {#Sec7}
=======

Study Population {#Sec8}
----------------

The ITT population in the UMEC/VI 62.5/25 and TIO group consisted of 1747 patients, of which 533 patients formed the MN subgroup of interest. The other treatment arms (UMEC 125.25, VI 25, and UMEC 125) comprised 850 patients in total but were not included in the analysis as they are unlicensed medications and doses. Although certain patient demographics such as age, sex, and reversibility were similar in the ITT and MN populations, there were some notable differences (Table [1](#Tab1){ref-type="table"}). More patients in the MN subgroup were current smokers than in the ITT population (65% vs. 52% in patients treated with UMEC/VI and 60% vs. 51% in patients treated with TIO). As expected, more patients in the MN subgroup had moderate COPD (GOLD stage II) than severe/very severe COPD (GOLD stage III/IV), and post-albuterol % predicted FEV~1~ was higher in the MN population.Table 1Patient demographics and baseline characteristicsITT populationMN populationUMEC/VI 62.5/25\
(*N* = 878)TIO\
(*N* = 869)UMEC/VI\
62.5/25\
(*N* = 275)TIO\
(*N* = 258)Age, years, mean (SD)63.0 (8.6)63.4 (8.7)61.7 (8.6)62.3 (8.7)Male, *n* (%)596 (68)594 (68)194 (71)165 (64)Current smoker at screening^a^, *n* (%)457 (52)439 (51)180 (65)155 (60)Smoking pack-years^b^, *n* (%)45.1 (25.6)46.1 (27.0)47.1 (25.6)49.5 (30.1)Reversible to albuterol^c,d^, *n* (%)243 (28)248 (29)94 (34)77 (30)Post-albuterol% predicted FEV~1~ Mean (SD)^e^47.0 (13.1)47.0 (12.99)50.9 (12.27)50.1 (12.84)GOLD stage, *n* ^f^\* (%) II393 (45)385 (44)154 (56)141 (55) III372 (42)375 (43)103 (38)94 (37) IV111 (13)106 (12)17 (6)22 (9)ICS use at screening^g^, *n* (%) Yes443 (50)445 (51)00Exacerbation history^h^, *n* (%) Required corticosteroid and/or antibiotic (without hospitalization)193 (22)215 (25)57 (21)45 (17) Required hospitalization73 (8)80 (9)18 (7)20 (7)*FEV* ~*1*~ forced expiratory volume in 1 s, *GOLD* global initiative for chronic obstructive lung disease, *ICS* inhaled corticosteroid, *ITT* intent to treat, *MN* maintenance-naïve, *SD* standard deviation, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol^a^Patient reclassified as current smoker if smoked within 6 months^b^Smoking pack-years = (number of cigarettes smoked per day/20) × number of years smoked^c^Reversibility was defined as an increase in FEV~1~ of ≥12% and ≥200 ml following administration of albuterol^d^ITT population: UMEC/VI, *n* = 876; TIO, *n* = 863^e^ITT population: UMEC/VI, *n* = 876; TIO, *n* = 866, MN population: UMEC/VI, *n* = 274; TIO *n* = 257^f^UMEC/VI, *n* = 873; TIO, *n* = 859^g^ICS use was defined as those patients who were currently taking ICS medications at the screening visit^h^Patients experiencing ≥1 exacerbation during the 12 months prior to screening

Efficacy {#Sec9}
--------

Trough FEV~1~: In both the MN and ITT populations, UMEC/VI was associated with statistically significant improvements compared with TIO in trough FEV~1~ from day 2. At day 169 mean improvements in trough FEV~1~ from baseline were significantly greater for UMEC/VI versus TIO in both populations\' least squares (LS) mean difference \[95% confidence interval (CI)\]: MN population: 146 ml (102--189); *P* \< 0.001; ITT population: 95 ml (71--118), *P* \< 0.001 (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Trough FEV~1~ changes over time in the ITT and MN populations. *CI* confidence interval, *FEV* ~*1*~ forced expiratory volume in 1 s, *ITT* intent to treat, *LS* least squares, *MN* maintenance-naïve, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol

Health-related quality of life: UMEC/VI and TIO provided mean improvements (≥4-unit decrease) from baseline in total SGRQ score, in both the MN and ITT populations, throughout the study (Fig. [2](#Fig2){ref-type="fig"}). Improvements versus baseline were numerically greater in the MN population compared with the ITT population for both treatment regimens at all visits. SGRQ total scores were significantly improved with UMEC/VI versus TIO in the ITT population on day 28 (−2.25 units, 95% CI: −3.26 to −1.23; *P* \< 0.001) and day 84 (−1.63: 95% CI: −2.76 to −0.49; *P* = 0.005), but not on day 168 (−0.93; 95% CI: −2.19 to 0.33; *P* = 0.149) (Fig. [2](#Fig2){ref-type="fig"}). In the smaller MN population, the SGRQ treatment differences were in favor of UMEC/VI at all time points, but were not significant (Fig. [2](#Fig2){ref-type="fig"}).Fig. 2SGRQ total score mean change from baseline in the ITT and MN populations. *CI* confidence interval, *ITT* intent to treat, *LS* least squares, *MCID* minimal clinically important difference, *MN* maintenance-naïve, *SGRQ* St George's respiratory questionnaire, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol

The odds of being an SGRQ responder (≥4-unit decrease) versus a non-responder was significantly greater with UMEC/VI treatment compared with TIO treatment at days 28 and 84 in the ITT population (OR: 1.3 at both time points; *P* = 0.007 day 28; *P* = 0.009 day 84), but was not significantly different in the MN population (Table S1). At day 168, the odds of being a responder versus a non-responder were not significantly different between treatment groups in either the MN or ITT populations (Table S1).

Rescue medication use: The percentage of patients achieving a response in rescue-free episodes was significantly greater with UMEC/VI compared with TIO in both the ITT \[46% vs. 36%; OR: 1.5 (95% CI: 1.2--1.9)\] and MN \[47% vs. 37%; OR: 1.5 (95% CI: 1.0--2.2)\] populations (Table [2](#Tab2){ref-type="table"}). The mean number of puffs/day over weeks 1--24 was improved for UMEC/VI versus TIO in both the ITT and MN populations \[difference (ITT): −0.5 (95% CI: −0.8 to −0.3) puffs/day; *P* \< 0.001; (MN): −0.5 (95% CI: −0.9 to 0.0); *P* = 0.066\].Table 2Summary and analysis of rescue medication useRescue use, puffs/day, weeks 1--24UMEC/VITIOITT population, *n*776764LS mean change from baseline (SE)−2.0 (0.09)−1.40 (0.10)UMEC/VI vs. TIO, OR (95% CI)−0.5 (−0.8 to −0.3)\*MN population, *n*241225LS mean change from baseline (SE)−1.6 (0.18)−1.1 (0.18)UMEC/VI vs. TIO, OR (95% CI)−0.5 (−0.9 to 0.0)^‡^Rescue-free episodesITT population, *n* ^‡^776764Patients achieving increase^a^, *n*(%)357 (46)273 (36)UMEC/VI vs. TIO, OR (95% CI)1.5 (1.2 to 1.9)\*MN population, *n* ^‡^241225Patients achieving increase, *n*(%)114 (47)84 (37)UMEC/VI vs. TIO, OR (95% CI)1.5 (1.0 to 2.2)^§^*CI* confidence interval, *ITT* intent to treat, *LS* least squares, *MN* maintenance-naïve, *OR* odds ratio, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol\**P* \< 0.001, ^†^ *P* \< 0.01; ^§^ *P* \< 0.05, ^‡^ *P* = 0.066 for UMEC/VI vs. TIO^‡^ *n* is the number of patients with analyzable data at the current time point^a^Patients demonstrating a treatment effect similar to 1 extra rescue-free month per year or 2 extra rescue-free weeks in 24 (a change from baseline ≥8.3% over weeks 1--24)

The proportion of patients with a short-term composite CID was lower with UMEC/VI treatment versus TIO treatment in both populations (MN population: 41% vs. 55%; ITT population: 41% vs. 56%). The risk of a first CID was reduced with UMEC/VI compared with TIO in the MN population \[HR = 0.66 (0.51--0.85); *P* = 0.001\] (Fig. [3](#Fig3){ref-type="fig"}). Similar results were observed for UMEC/VI treatment versus TIO in the ITT population \[HR (95% CI) = 0.62 (0.54 to 0.71); *P* \< 0.001\] (Fig. [3](#Fig3){ref-type="fig"}).Fig. 3Time to first CID in the **a** ITT and **b** MN populations. *CID* clinically important deterioration, *ITT* intent to treat, *MN* maintenance-naïve, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol, *HR* hazard ratio, *CI* confidence interval

When the individual components of a first short-term CID were assessed, a significant reduction in the risk of deterioration in lung function was observed for UMEC/VI treatment versus TIO in both the MN and ITT populations (Table [3](#Tab3){ref-type="table"}). The risk of a CID on SGRQ total score was also significantly reduced with UMEC/VI treatment compared with TIO, but only in the ITT population (Table [3](#Tab3){ref-type="table"}). There was no significant difference between the treatment groups in the risk of a moderate-to-severe exacerbation in either population.Table 3Summary and analysis of first deterioration events in the ITT and MN populationsComponents of the first CIDUMEC/VI 62.5/25TIOHazard ratio, UMEC/VI vs. TIO\
(95% CI)ITT population, *n*878869 ≥100 ml decrease in trough FEV~1~159 (18)308 (35)0.44 (0.36 to 0.53)\* ≥4-unit SGRQ total score increase208 (24)236 (27)0.83 (0.69 to 1.00)^†^ Moderate-to-severe COPD exacerbation56 (6)54 (6)1.02 (0.70 to 1.48)MN population, *n*275258 ≥100 ml decrease in trough FEV~1~53 (19)93 (36)0.44 (0.32 to 0.62)\* ≥4-unit SGRQ total score increase66 (24)69 (27)0.92 (0.65 to 1.29) Moderate-to-severe COPD exacerbation13 (5)9 (3)1.33 (0.57 to 3.13)Data presented as *n* (%) unless otherwise indicated*CI* confidence interval, *CID* clinically important deterioration, *COPD* chronic obstructive pulmonary disease, *FEV* ~*1*~ forced expiratory volume in 1 s, *ITT* intent to treat, *MN* maintenance-naïve, *SGRQ* St George's respiratory questionnaire, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol\**P* \< 0.001, ^†^ *P* \< 0.05

Risk of sustained CID: The proportion of patients with a sustained CID was approximately half of that observed for the first CID and was lower for UMEC/VI versus TIO in both the MN population (22% vs. 30%) and the ITT population (21% vs. 30%). The risk of a sustained CID was significantly reduced in the UMEC/VI treatment group versus the TIO treatment group, for both the MN and ITT populations \[MN population: HR = 0.69 (0.49 to 0.97); *P* \< 0.05\]; ITT population: HR = 0.64 (0.53 to 0.77), *P* \< 0.001; (Table S2)\].

Safety: Overall, the incidences of AEs were similar for the two treatment groups in both the ITT and MN populations, with nasopharyngitis and headache reported most frequently. One exception was a lower incidence of upper respiratory tract infection in the UMEC/VI treatment group compared with TIO in the MN population \[2 vs. 10 patients (\<1% vs. 4%)\]. The incidences of non-fatal serious AEs and fatal AEs were also similar between both populations (Table [4](#Tab4){ref-type="table"}). Pneumonia and cardiovascular events occurred in \<1% in the UMEC/VI and TIO groups (in both populations).Table 4Summary of AEsITT populationMN populationUMEC/VI\
(*N* = 878)TIO\
(*N* = 869)UMEC/VI\
(*N* = 275)TIO\
(*N* = 258)AEs reported by ≥3% of patients on any treatment, *n*(%) Nasopharyngitis63 (7)62 (7)18 (7)15 (6) Headache80 (9)55 (6)20 (7)15 (6) Back pain27 (3)28 (3)8 (3)4 (2) Cough25 (3)26 (3)5 (2)8 (3) Upper respiratory tract infection17 (2)26 (3)2 (\<1)10 (4)AEs of special interest Cardiovascular events (any)2 (\<1)2 (\<1)01 (\<1) Pneumonia2 (\<1)6 (\<1)01 (\<1)On-treatment non-fatal SAEs Any event, *n*(%)42 (5)35 (4)8 (3)11 (4)Fatal AEs^a^ Any event, *n*(%)4 (\<1)7 (\<1)3 (1)2 (\<1)*AE* adverse event, *COPD* chronic obstructive pulmonary disease, *ITT* intent to treat, *MN* maintenance-naïve, *SAE* serious adverse event, *TIO* tiotropium, *UMEC* umeclidinium, *VI* vilanterol^a^Deaths were attributable to the following: *ITT*: cardiac arrest, cardiac failure, COPD, and hemorrhagic stroke in the UMEC/VI group; cardiac failure, pulmonary embolism, respiratory arrest, respiratory failure, upper gastrointestinal hemorrhage, sudden death, and pancreatic carcinoma in the TIO group. *MN*: Cardiac arrest, hemorrhagic stroke, and COPD in the UMEC/VI group; respiratory arrest and respiratory failure in the TIO group

Discussion {#Sec10}
==========

This is the first analysis to compare the differences between UMEC/VI and TIO in a MN COPD population, looking at indices of both improvement and deterioration including the novel composite endpoint of short-term CID, which encompasses multiple elements and measurement of short-term worsening in COPD advocated in current guidelines.

In this analysis, UMEC/VI provided improvements in trough FEV~1~ from baseline compared with TIO in both the MN and ITT populations, with the largest magnitude of effect seen in MN patients. The greater treatment effect on trough FEV~1~ in the MN population could, in part, be related to reduced confounding because of background ICS therapy, but may also be due to patients with less impaired lung function having greater capacity to benefit from increased bronchodilator therapy \[[@CR14]\]. Consistent with this, a recent study assessing the efficacy of TIO plus olodaterol versus TIO monotherapy also demonstrated improvements from baseline in trough FEV~1~ that tended to be greater in patients with less severe COPD and who were LAMA or LABA naïve \[[@CR4]\].

This study also assessed the effect of UMEC/VI and TIO treatment on the composite endpoint of short-term CID, which is designed to address clinically important early signs of deterioration in lung function, health status, and/or COPD exacerbations. A recent study has demonstrated the dual bronchodilator therapy may reduce the risk of short-term CID and potentially provide greater airway stability compared with monotherapy \[[@CR15]\].

One additional potential advantage of the CID approach is that it provides a means to assess symptomatic patients, including MN patients at risk of deterioration at an early stage in the course of COPD, potentially providing useful information on how to prevent deterioration and maintain stability or when to escalate therapy.

This analysis demonstrated that UMEC/VI reduced the risk of a first composite short-term CID compared with TIO to a similar extent in both the ITT and MN populations. These preliminary results in MN patients provide additional insight into the potential benefits of optimizing lung function in low-risk symptomatic patients with COPD. The improved bronchoprotection seen with dual bronchodilators versus monotherapy in both the MN and ITT cohorts in this analysis may be indicative of more prolonged disease stability. Further, validation of this endpoint is ongoing to better understand the long-term consequences of short-term CID on morbidity and mortality over several years of follow-up \[[@CR16]\].

Previous studies have demonstrated an accelerated lung function decline in patients with moderate compared with severe and very severe COPD; therefore, optimizing bronchodilator treatment at an earlier stage may provide longer term benefits \[[@CR1], [@CR2], [@CR17]\]. In support of this, early maintenance treatment with TIO was shown to be associated with long-term sustained benefits in the 4-year UPLIFT study, with a slower decline in lung function and HRQoL \[[@CR3], [@CR18]\]. In a previous publication, which examined time to a first CID with UMEC/VI versus TIO and placebo in both GOLD B and D subgroups, no apparent differences were found in the magnitude of treatment benefit on the incidence of CID based on levels of lung function impairment or disease severity at baseline \[[@CR15]\]. The current study focused on patients from three similar studies with a large proportion of symptomatic COPD patients (all mMRC ≥2), 55% and 45% of the ITT and MN subgroups, respectively, presenting with severe lung function impairment at baseline. The current findings are commensurate with the earlier study by Singh and colleagues \[[@CR15]\], highlighting that reducing the risk of a first CID is as likely in low and high risk patients and when using dual bronchodilators as first- or second-line therapy. It is therefore important that the early use of dual therapy was compared with monotherapy in this MN population.

Safety data were similar for both the MN and ITT populations when comparing UMEC/VI and TIO. A low number of serious AEs \[including few cardiac events and incidences of pneumonia (≤2% in any treatment group)\] and a low mortality rate (≤1%) were reported with each treatment in each population. As such, the data present no increased safety concern for the earlier use of UMEC/VI compared with LAMA monotherapy in the course of COPD treatment. This is also supported by the results of a recent network meta-analysis that demonstrated no increased safety signal for LAMA/LABAs versus either mono LAMAs or LABAs \[[@CR19]\].

One key limitation of the study is the retrospective nature of the findings. Additionally, only patients with moderate-to-severe breathlessness were included in the original clinical studies comparing UMEC/VI and TIO, and all patients had a low exacerbation risk. Consequently, it is possible that patients who are less symptomatic than those studied here could be managed on monotherapy. Also, exacerbations as a deterioration parameter had limited potential to feature strongly in this short-term analysis. Therefore, a longer follow-up may mean that exacerbations feature more prominently in the CID endpoint in low-risk patients receiving bronchodilators without concurrent ICS. Whilst the occurrence of short-term CID has been linked with long-term poor outcomes, further validation of the CID endpoint in prospective trials of increased duration are needed to better understand long-term outcomes in COPD with dual- versus mono-bronchodilator therapy.

Conclusions {#Sec11}
===========

The efficacy and safety data presented here support the use of dual-bronchodilator therapy as the first-line maintenance treatment option in patients with moderate-to-severe breathlessness and a low risk of exacerbations. The impact of dual- versus mono-bronchodilator therapy on the natural history of COPD requires validation with long-term prospective studies.
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